RxDoctor Payments DataLook up a doctor →

Jorge Galan, DO

Gastroenterology · Columbia, SCNPI 1598746612

Payments from drug & device makers

$13,487in general payments, 2019–2025

Across 790 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Pfizer$629
  • Takeda Pharmaceuticals U.S.A., Inc.$618
  • Bristol Myers Squibb$585
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$320%
  • Food & beverage$13,12797%
  • Education$3272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,487 in reported general payments places this provider in the 75th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$184,906
Medicare patients
696
Services billed
1,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab20$552,418
Humira(Cf) PenAdalimumab22$280,948
XifaxanRifaximin11$38,340
LinzessLinaclotide28$25,143
Mesalamine41$21,864
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates229$15,404
LialdaMesalamine13$14,365
Budesonide EcBudesonide22$12,519
Mesalamine ErMesalamine12$9,291
Azathioprine36$5,492
Budesonide DrBudesonide34$5,108
ClenpiqSod Picosulf/Mag Ox/Citric Ac19$3,255
Pantoprazole Sodium233$3,102
Omeprazole117$2,168
Famotidine48$1,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,086$552,41820 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,052$38,34011 claims
AbbVieLinzess$4,212$25,14328 claims
Ferring Pharmaceuticals Inc.Clenpiq$200$3,25519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →